Get started
Author

Isabel Ruth Preeshagul

Observed names: I. Preeshagul, I.R. Preeshagul, Isabel Preeshagul, Isabel R Preeshagul, Isabel R. Preeshagul, Preeshagul IR
Observed institutions: Mount Sinai Beth Israel, Northwell Health, Hackensack University Medical Center, Memorial Sloan Kettering Cancer Center, Hofstra University, Cornell University, Weill Cornell Medicine
ORCID: 0000-0002-4504-4520
Observed ORCID: 0000-0002-4504-4520
OpenAlex ID: A5058327046
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study
2023 · Chiaojung Jillian Tsai, Chiaojung Jillian Tsai, et al. · The Lancet · 283
COVID-19 in patients with lung cancer
2020 · J. Luo, H. Rizvi, et al. · Annals of Oncology · 267
PDF
Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers
2020 · Jia Luo, Hira Rizvi, et al. · Cancer Discovery · 232
PDF
Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer
2022 · Justin Jee, Emily S. Lebow, et al. · Nature Medicine · 194
PDF
Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC
2020 · Matthew D. Hellmann, Barzin Y. Nabet, et al. · Clinical Cancer Research · 125
Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices
2019 · Natasha Rekhtman, Patrice Desmeules, et al. · Modern Pathology · 89
PDF
Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression ― Interim Analysis of the First Randomized Study of Stereotactic Body Radiotherapy in Patients With Oligoprogressive Metastatic Cancers of the Lung and Breast
2021 · C.J. Tsai, J.T. Yang, et al. · International Journal of Radiation Oncology*Biology*Physics · 68
Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline
2023 · Humera Khurshid, Nofisat Ismaila, et al. · Journal of Clinical Oncology · 60
PDF
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics
2021 · Laura Mezquita, Isabel Preeshagul, et al. · European Journal of Cancer · 57
Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non–Small Cell Lung Cancer
2023 · Rohit Thummalapalli, Ezra Bernstein, et al. · JCO Precision Oncology · 42
PDF
Potential biomarkers for predicting outcomes in CABG cardiothoracic surgeries
2013 · Isabel Preeshagul, Rajendra Gharbaran, et al. · Journal of Cardiothoracic Surgery · 39
PDF
Final Analysis of Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression Trial - A Randomized Study of Stereotactic Body Radiotherapy for Oligoprogressive Metastatic Lung and Breast Cancers
2022 · C.J. Tsai, J.T. Yang, et al. · International Journal of Radiation Oncology*Biology*Physics · 36
A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer
2024 · Noura J. Choudhury, W. Victoria Lai, et al. · Clinical Cancer Research · 33
PDF
New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
2017 · Nagashree Seetharamu, Isabel Preeshagul, et al. · Lung Cancer Targets and Therapy · 33
PDF
Therapeutic Effects of Repurposed Therapies in Non-Small Cell Lung Cancer: What Is Old Is New Again
2015 · Ashish Saxena, Daniel Becker, et al. · The Oncologist · 33
PDF
Treatment of Cancer-Associated Retinopathy With Rituximab
2013 · Irene Dy, Rangaswamy Chintapatla, et al. · Journal of the National Comprehensive Cancer Network · 32
PDF
Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab
2021 · Maria Thor, Annemarie F. Shepherd, et al. · Radiotherapy and Oncology · 22
Acquired resistance to PD-1 blockade in NSCLC.
2020 · Adam Jacob Schoenfeld, Hira Rizvi, et al. · Journal of Clinical Oncology · 17
Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update
2024 · Gregory P. Kalemkerian, Humera Khurshid, et al. · Journal of Clinical Oncology · 16
PDF
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study
2023 · Arielle Elkrief, Joao M. Victor Alessi, et al. · Journal for ImmunoTherapy of Cancer · 15
PDF
Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer
2024 · Jessica R. Bauman, Geoffrey Liu, et al. · Lung Cancer · 14
PDF
Evaluating of HPV–DNA ISH as an Adjunct to p16 Testing in Oropharyngeal Cancer
2020 · Jeffrey Chi, Isabel R Preeshagul, et al. · Future Science OA · 13
PDF
Pilot Study of Dacomitinib for Patients With Metastatic EGFR-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib
2021 · Noura J. Choudhury, Alex Makhnin, et al. · JCO Precision Oncology · 11
PDF
Long-term responders to PD-1 blockade in patients with advanced non-small cell lung cancer (NSCLC).
2020 · Jia Luo, Chaitanya Bandlamudi, et al. · Journal of Clinical Oncology · 10
Exploring published and novel pre-treatment CT and PET radiomics to stratify risk of progression among early-stage non-small cell lung cancer patients treated with stereotactic radiation
2023 · Maria Thor, Kelly Fitzgerald, et al. · Radiotherapy and Oncology · 9
Works count: 125
Citation count: 1,809
H-index: 17
I10-index: 24
Year
Topic
Type